Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia
Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia
复制标题
DOI：
10.3892/ol.2012.753
复制
发表时间：
2012-09-01
期刊：
影响因子：
2.9
通讯作者：
Hoshino, Tomoaki
中科院分区：
文献类型：
--
作者：
Kinoshita, Takashi;Azuma, Koichi;Hoshino, Tomoaki
特发性间质性肺炎（IIP）被认为是肺癌（LC）的危险因素之一。然而，肺癌合并特发性间质性肺炎患者的治疗方案尚未明确。在本研究中，我们探讨了化疗对非小细胞肺癌（NSCLC）合并特发性间质性肺炎（NSCLC - IIP）患者的可行性和疗效。我们回顾性分析了22例接受化疗的NSCLC - IIP患者。为了确定特发性间质性肺炎如何影响非小细胞肺癌的临床结局，将这些患者与276例未合并特发性间质性肺炎且仅接受化疗的非小细胞肺癌患者进行了比较。化疗的NSCLC - IIP患者的缓解率（部分缓解 + 病情稳定）为72.3%（17/22），而急性加重（AE）发生率为13.6%（3/22）。与未合并特发性间质性肺炎的非小细胞肺癌患者相比，NSCLC - IIP患者的生存期明显更短（P
Idiopathic interstitial pneumonia (IIP) is considered to be one of the risk factors for lung cancer (LC). However, therapeutic options for patients with LC complicated by LIP are not well established. In this study, we investigated the feasibility and efficacy of chemotherapy for patients with non-small cell lung cancer (NSCLC) complicated by IIP (NSCLC-IIP). We retrospectively analyzed 22 NSCLC-IIP patients who received chemotherapy. To determine how IIP affected the clinical outcomes in NSCLC, they were compared with 276 NSCLC patients without IIP, who were treated with chemotherapy alone. The response rate (partial response + stable disease) was 72.3% (17/22), whereas the incidence of acute exacerbation (AE) was 13.6% (3/22) in NSCLC-IIP patients treated with chemotherapy. NSCLC-IIP patients had significantly shorter survival compared with NSCLC patients without IIP (P